CBD Life Sciences Inc. Logo

CBD Life Sciences Inc.

CBDL

(1.2)
Stock Price

0,00 USD

-24.61% ROA

-35.14% ROE

-259.03x PER

Market Cap.

70.844,00 USD

0% DER

0% Yield

-75.69% NPM

CBD Life Sciences Inc. Stock Analysis

CBD Life Sciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CBD Life Sciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-2260.94%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-224.18%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

CBD Life Sciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CBD Life Sciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

CBD Life Sciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CBD Life Sciences Inc. Revenue
Year Revenue Growth
2011 0
2012 0 0%
2013 155.553 100%
2014 122.789 -26.68%
2015 0 0%
2019 79.635 100%
2020 225.897 64.75%
2021 59.257 -281.22%
2022 160.241 63.02%
2023 167.148 4.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CBD Life Sciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CBD Life Sciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 44.117
2012 53.292 17.22%
2013 442.901 87.97%
2014 752.488 41.14%
2015 69.232 -986.91%
2019 337 -20443.62%
2020 315 -7.32%
2021 1.386 77.33%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CBD Life Sciences Inc. EBITDA
Year EBITDA Growth
2011 -52.743
2012 -59.141 10.82%
2013 -304.827 80.6%
2014 -737.700 58.68%
2015 -73.792 -899.7%
2019 -869.620 91.51%
2020 -384.090 -126.41%
2021 -5.128.240 92.51%
2022 -806.240 -536.07%
2023 2.920 27710.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CBD Life Sciences Inc. Gross Profit
Year Gross Profit Growth
2011 0
2012 0 0%
2013 155.553 100%
2014 122.789 -26.68%
2015 0 0%
2019 36.633 100%
2020 -212.230 117.26%
2021 -148.249 -43.16%
2022 -280.260 47.1%
2023 14.248 2067.01%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CBD Life Sciences Inc. Net Profit
Year Net Profit Growth
2011 -52.743
2012 -156.334 66.26%
2013 -367.135 57.42%
2014 -780.139 52.94%
2015 -86.872 -798.03%
2019 -861.010 89.91%
2020 -1.694.396 49.18%
2021 -5.128.242 66.96%
2022 -859.804 -496.44%
2023 2.908 29666.85%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CBD Life Sciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -894
2012 -2.405 62.87%
2013 -2.295 -4.84%
2014 -428 -435.98%
2015 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CBD Life Sciences Inc. Free Cashflow
Year Free Cashflow Growth
2011 -48.908
2012 -141.063 65.33%
2013 -486.932 71.03%
2014 -792.703 38.57%
2019 -1.842.132 56.97%
2020 -500.637 -267.96%
2021 -5.309.093 90.57%
2022 -1.026.318 -417.3%
2023 1.025 100228.59%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CBD Life Sciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -48.908
2012 -141.063 65.33%
2013 -486.932 71.03%
2014 -792.703 38.57%
2019 -1.842.132 56.97%
2020 -500.637 -267.96%
2021 -5.147.542 90.27%
2022 -957.318 -437.7%
2023 1.025 93496.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CBD Life Sciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2019 0 0%
2020 0 0%
2021 161.551 100%
2022 69.000 -134.13%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CBD Life Sciences Inc. Equity
Year Equity Growth
2011 476.780
2012 403.296 -18.22%
2013 82.376 -389.58%
2014 -13.366 716.31%
2015 209.295 106.39%
2019 1.031.245 79.7%
2020 -20.380 5160.08%
2021 1.332.962 101.53%
2022 473.158 -181.72%
2023 394.584 -19.91%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CBD Life Sciences Inc. Assets
Year Assets Growth
2011 444.346
2012 430.796 -3.15%
2013 662.896 35.01%
2014 632.082 -4.88%
2015 620.893 -1.8%
2019 1.491.591 58.37%
2020 143.716 -937.87%
2021 1.363.357 89.46%
2022 473.158 -188.14%
2023 419.327 -12.84%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CBD Life Sciences Inc. Liabilities
Year Liabilities Growth
2011 -32.434
2012 27.500 217.94%
2013 580.520 95.26%
2014 645.448 10.06%
2015 411.598 -56.82%
2019 460.346 10.59%
2020 164.096 -180.53%
2021 30.395 -439.88%
2022 0 0%
2023 24.743 100%

CBD Life Sciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-259.03x
Price To Sales Ratio
0.42x
POCF Ratio
10394.9
PFCF Ratio
36.18
Price to Book Ratio
51.58
EV to Sales
0.41
EV Over EBITDA
-2.97
EV to Operating CashFlow
34.9
EV to FreeCashFlow
34.9
Earnings Yield
-0
FreeCashFlow Yield
0.03
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
-0.02
ROE
-0.19
Return On Assets
-0.31
Return On Capital Employed
-0.39
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-0.76
Effective Tax Rate
0.41

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.21
Operating Profit Margin
-0.76
Pretax Profit Margin
-0.76
Net Profit Margin
-0.76

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.2
Return on Tangible Assets
-0.25
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
38.44
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
9.5
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.11
Current Ratio
8.06
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
18612.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CBD Life Sciences Inc. Dividends
Year Dividends Growth

CBD Life Sciences Inc. Profile

About CBD Life Sciences Inc.

CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.

CEO
Ms. Lisa Anne Nelson
Employee
3
Address
10855 N 116th Street
Scottsdale, 85259

CBD Life Sciences Inc. Executives & BODs

CBD Life Sciences Inc. Executives & BODs
# Name Age
1 Ms. Lisa Anne Nelson
Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer & Director
70
2 Mr. Matthew McGee
Chief Marketing Officer
70
3 Ms. Brianna Nelson
Chief Product Developer & Director
70

CBD Life Sciences Inc. Competitors